Polycystic Ovary Syndrome in Type 1 Diabetes

Pathogenesis of Functional Hyperandrogenism in Women With Type 1 Diabetes Mellitus: From Genetic-molecular Mechanisms to Clinical Phenotype.

BACKGROUND Functional ovarian hyperandrogenism, including the polycystic ovary syndrome (PCOS), is very prevalent in women with type 1 diabetes (T1D). The pathogenic mechanisms of this association remain unclear.

HYPOTHESIS Individual factors expose or protect women with T1D to/from the development of androgen excess and PCOS. Such androgen excess in women with T1D may increase their cardiometabolic risk.

MAIN OBJECTIVE Unveiling the pathogenic mechanisms behind functional hyperandrogenism in women with T1D from a sex/gender-medicine and sexual dimorphism perspective.

MATERIAL AND METHOS We have designed a cross-sectional comparative clinical study, including 5 groups of study subjects with 12 participans per group:

i) Women with T1D & PCOS. ii) Women with T1D without PCOS. iii) Men with T1D and normal gonadal function. iv) Women with PCOS without diabetes mellitus v) Non-hyperandrogenic control women without T1D. All groups will show similar age and body mass index. T1D groups will be matched for duration of disease.

OUTCOMES 1.1 Insulin sensitivity (hyperinsulinaemic euglycaemic clamping). 1.2 Body composition (dual-energy x-ray absorptiometry, bioelectrical impedance analysis & sonographic studies).

1.3 Ovarian and adrenal steroidogenesis. 2.1 Differential pattern in genetic variants related with insulin signalling and response, inflammation, adiposity, gonadal function, steroidogenesis, and PCOS itself by whole exome sequencing.

2.2 Microbiopsy studies in deep subcutaneous adipose tissue and skeletal muscle tissue: 2.2.1 Differential DNA methylation patterns in genes associated with PCOS. 2.2.2 Differential transcriptomic pattern in genes associated with PCOS.

2.2.3 Differential proteomic patterns in adipose and muscle tissues. 3. Interaction between T1D and PCOS on parameters of metabolic control (intersticial blood glucose monitoring) and morbidities associated with T1D itself.

Study Overview

• Status: Not yet recruiting
• Conditions: Type 1 Diabetes Mellitus; Polycystic Ovary Syndrome (PCOS)
• Intervention / Treatment: Other: Type 1 diabetes mellitus; Other: Sex dimorphism; Other: Elevated circulating androgen levels

Detailed Description

Functional ovarian hyperandrogenism, and its most frequent phenotypic expression, polycystic ovary syndrome (PCOS), has a worldwide prevalence similar to that of other pandemic metabolic entities such as type 2 diabetes, with figures ranging from 6.5% of women in our environment using strict classical criteria to 17-21% of premenopausal women from Europe and the United States, according to the most recent and inclusive diagnostic criteria. Almost all classic and non-classic cardiovascular risk factors cluster in women with this condition from their early lifespan. Conditions such as obesity, type 2 diabetes, hypertension, or dyslipidaemia, place this prevalent population at a higher risk of cardiovascular events compared to non-hyperandrogenic women. PCOS is a complex syndrome with familial aggregation, in which protective and facilitating environmental factors trigger the onset of the hyperandrogenic phenotype and its metabolic repercussions on a predisposing genotype.

POLYCYSTIC OVARY SYNDROME AND TYPE 1 DIABETES MELLITUS One of the metabolic events inherent to PCOS is a deficient organ-dependent insulin action primarily at the liver. Acting upon this central defect, obesity is the major contributor to peripheral insulin resistance in these women. Since insulin acts as a co-gonadotrophin on theca cells by stimulating various enzymes involved in ovarian and adrenal steroidogenesis, any condition associating endogenous hyperinsulinism, such as obesity or type 2 diabetes, may be associated with PCOS. However, our research group first described the association between PCOS and T1D more than 20 years ago. In that pivotal publication these adolescent and young adult women, who suffered from complete impairment of insulin secretion as the primary mechanism of disease instead of insulin resistance and compensatory hyperinsulinism, had a 3-fold increase in the prevalence of classic PCOS compared with unselected non-hyperandrogenic women from the general population.

This association has been confirmed in subsequent studies conducted by different groups worldwide. In a recent meta-analysis and systematic review by our group, we reported an increased prevalence of PCOS; in its upper range, such prevalence might reach 34% of patients with T1D, tripling the figures observed in the general population for the classic PCOS phenotype, which is the most severe in terms of cardiometabolic consequences. From a pathophysiological view, and given the obvious absence of endogenous hyperinsulinism in T1D, this relationship must be necessarily supported by exogenous subcutaneous insulin delivery. In healthy subjects, insulin directly reaches the liver through the portal circulation after its pancreatic secretion. After exerting its actions at this level, with its subsequent hepatic clearance, insulin passes into the systemic circulation at much lower concentrations than those found in the portal circulation. In PCOS and other insulin-resistant states, insulin resistance is compensated by increased pancreatic insulin secretion, resulting in portal and systemic hyperinsulinism. In contrast, in subjects with T1D, insulin is administered subcutaneously (non-physiologically) and exerts its actions on different organs and tissues, including the gonads and adrenal cortex, before reaching liver tissue at concentrations sufficient to suppress gluconeogenesis; hence, systemic insulin concentrations are necessarily supraphysiological for this reason. In contrast, hepatic insulin levels are not excessive, since this would precipitate hypoglycaemia, and this explains the constant finding of normal levels of sex hormone binding globulin (SHBG) in women with T1D and PCOS. In contrast, in women with PCOS without T1D, SHBG synthesis and secretion is decreased as a consequence of portal hyperinsulinism (certain adipokines secreted by visceral adipose tissue also contribute to this inhibition), a situation that does not occur in women with T1D in the absence of hepatic hyperinsulinism.

A few studies have reported a negative interaction between T1D and PCOS in terms of micro- or macrovascular complications. Nevertheless, the possibility that androgen excess negatively affects adipose tissue distribution in women with T1D and PCOS is plausible, placing them at risk for increased abdominal adiposity and insulin resistance. On the other hand, similarly to those women at high risk of PCOS in the general population - for example, those with obesity, even extreme obesity, or first-degree relatives of women with PCOS - who do not develop characteristics of the syndrome, not all patients with T1D, universally treated with subcutaneous insulin, will develop PCOS, indicating that a predisposition to PCOS is a conditio sine qua non for its occurrence.

DEFECTS IN OVARIAN AND ADRENAL STEROIDOGENESIS Both the fact that PCOS is not universal in women with insulin resistance and hyperinsulinism, and that insulin resistance is not universal in all women with PCOS, suggests that there is a primary defect that favours androgen excess in affected women, and that this is essential for the development of the syndrome in response to insulin or other triggers. The elegant studies conducted by the McAllister's group 20 years ago at the University of Pennsylvania demonstrated that, after several passes in primary culture, theca cells from patients with PCOS produced an excess androgen secretion compared to those of control women without the syndrome. This occurred because an intrinsically increased expression and activity of the enzyme 17α-hydroxylase/17,20-desmolase (P450c17, CYP17), the qualitative regulatory enzyme of sex steroid synthesis that catalyses both the 17α-hydroxylation of pregnenolone and progesterone, and the conversion of 17α-hydroxypregnenolone to dehydroepiandrosterone. The 17,20-desmolase activity of the enzyme is regulated by post-transcriptional mechanisms, including phosphorylation of the serine/threonine residues of the enzyme itself. The same group also demonstrated increased expression in theca cells of women with PCOS of the P450scc enzyme, which is the quantitative regulatory enzyme of ovarian and adrenal steroidogenesis that catalyses the conversion of cholesterol to pregnenolone after cholesterol transfer from the outer to the inner mitochondrial membrane by the steroidogenesis acute regulatory protein (StAR). Since any factor that could influence these theca cells in vivo were, obviously, not present after several culture passes, these alterations place excessive androgen production as a primary ovarian defect in PCOS, corroborating clinical findings such as hyper-responsiveness of 17-hydroxyprogesterone to gonadotrophin stimulation or persistent hyperandrogenemia after suppression of adrenal steroidogenesis.

In about one third of women with PCOS, hyperandrogenism also has an adrenal component. An adrenal hyper-responsiveness to corticotrophin stimulation is common in women with PCOS and hyperandrogenism of adrenal origin. A decrease in peripheral 11β-hydroxysteroid dehydrogenase-dependent cortisol regeneration can induce a compensatory hyperactivation of the corticotrophic axis, and this defect can be found at the hepatic level in PCOS, induced by ovarian hyperandrogenism itself. Another factor related to adrenal activation would be the increased expression and activity of the 17α-hydroxylase/17,20-desmolase enzyme previously mentioned. Increased phosphorylation of the serine/threonine residues of this enzyme together with that of the serine residues of the insulin receptor substrate-1 (IRS-1) could constitute a common event linking ovarian and adrenal hyperandrogenism and insulin resistance. Additionally, a partial functional defect in the action of 3β-hydroxysteroid dehydrogenase could lead to the increased Δ5/Δ4 adrenal precursor ratio observed in some women with PCOS, either caused by the hyperinsulinism characteristic of the syndrome, or by common alterations in the regulation of 17α-hydroxylase/17,20-desmolase and 3β-hydroxysteroid dehydrogenase by the MEK/ERK signalling pathway.

ADIPOSITY, VISCERAL ADIPOSITY AND BODY COMPOSITION IN PCOS The contribution of obesity to gonadal dysfunction in women and men is well-known. Excess weight increases the prevalence of classical PCOS up to 4-fold in unselected women in our setting, and 30%-50% of women with extreme obesity have features consistent with a diagnosis of PCOS. Furthermore, the estimated prevalence of obesity in women with PCOS is close to 50%, although even more remarkable is the prevalence of central adiposity, derived from a 'masculinised' distribution of adipose tissue, consisting of visceral deposition. This visceral deposition may begin in childhood and during puberty, reinforcing the hyperandrogenic phenotype in predisposed girls. During adulthood, obesity and central adiposity worsen the cardiovascular profile of women with PCOS.

Androgen excess itself influences gene expression and the proteome of visceral adipose tissue, and thus a male-like pattern of adipokine expression in visceral adipose tissue has been described. Androgens are also potent inhibitors of adipogenic differentiation, limiting the number of adipocytes and their storage capacity in subcutaneous adipose tissue, so that androgen excess may limit the adaptive capacity of adipose tissue in women with PCOS by creating a state of lipotoxicity and dysfunctional adipocytokine secretion. Oxidative stress and subclinical chronic inflammation inherent to PCOS also play a role in the inability to physiological expansion of adipose tissue and its metabolic dysregulation. Ultimately, the interrelationship between PCOS and abdominal obesity is the result of a vicious circle in which androgenic excess favours the deposition of abdominal visceral fat, which directly facilitates androgenic excess of ovarian and adrenal origin through the secretion and effect of autocrine, paracrine and endocrine mediators [down-regulation of adiponectin and up-regulation of tumour necrosis factor-alpha (TNF-α), IL-6 and leptin], or indirectly through the induction of insulin resistance and compensatory hyperinsulinism.

INSULIN RESISTANCE, INFLAMMATION AND OXIDATIVE STRESS IN PCOS PATHOPHYSIOLOGY Euglycaemic clamp studies are consistent with a post-ligand binding defect in the insulin receptor affecting the intracellular metabolic signalling pathway in adipose tissue; an alteration supported by findings from metabolomic studies showing an increase in plasma long-chain fatty acids and glycerol, suggesting increased lipolysis, likely related to decreased sensitivity to insulin action in adipose tissue. Consistent with this, a substantial number of women with PCOS have increased phosphorylation of serine residues of the insulin receptor, whose function is inhibited by reducing the intrinsic kinase activity of its tyrosine residues. Such phosphorylation is mediated by TNF-α, especially in those patients with abdominal obesity, a scenario derived from the hyperandrogenic stimulus to the release of this cytokine by mononuclear cells, both after fasting and in response to glucose intake. In other women, phosphorylation of IRS-1 or activation of phosphatidylinositol-3-kinase aggravates insulin resistance. However, insulin resistance at the adipocyte level may also be mediated by another complementary mechanism, namely, the infiltration of this tissue by macrophages. Inflammatory macrophages characterised by CD11c expression cluster around adipocytes forming crown-like structures, the density of which directly correlates with the degree of insulin resistance. These macrophages will secrete cytokines such as TNF-α, promoting a local inflammatory environment. Women with PCOS show increased CD11c expression in macrophages and crown-like structures in subcutaneous adipose tissue in direct proportion to circulating testosterone levels. In muscle tissue of women with PCOS, the mitogenic pathway of the insulin receptor, MAPK-ERK 1/2, is also constitutively activated enhancing increased phosphorylation of IRS-1 serine residues. The presence of mitochondrial dysfunction in women with functional hyperandrogenism may contribute to the presence of insulin resistance. Oxidative stress induced by this mitochondrial dysfunction is involved in the pathogenesis of PCOS and metabolic complications related to hyperandrogenism. Although some studies have failed to confirm a primary impairment of mitochondrial function in PCOS, biomarkers of oxidative stress are increased in these women regardless of the presence of weight excess. Moreover, the alterations in mitochondrial function of hyperandrogenic women with insulin resistance resemble those of patients with type 2 diabetes.

GENETIC PREDISPOSITION PCOS is a complex multigenic condition that arises from the interaction between protective and predisposing genetic variants, which may have been selected over the ages by evolution due to an ancestral survival advantage, with environmental factors playing a determining role in the expression of the hyperandrogenic phenotype. Among others, genomic variants in genes regulating androgen biosynthesis, insulin action and inflammation may be associated with predisposition to PCOS. A meta-analysis of large-scale genome-wide association studies, including more than 10,000 women with PCOS and 100,000 controls, all of European origin, identified 14 loci associated with hyperandrogenism, gonadotrophin regulation and testosterone concentrations in affected women, and correlations with obesity, insulinemia, type 2 diabetes, lipid levels and coronary atherosclerotic disease, indicating a shared genetic architecture between these metabolic alterations and PCOS.

These pathophysiological mechanisms described in women with PCOS from the general population have not been studied in women with T1D. Therefore, the description of facilitating and protective factors associated with the development or absence of functional hyperandrogenism and PCOS in women with T1D is the main objective of the present research project.

HYPOTHESIS There are individual factors that expose or protect women with T1D to/from the development of androgen excess and PCOS, despite the iatrogenic systemic hyperinsulinism they all experience as a result of the subcutaneous administration of insulin they require for survival. Androgen excess in women with T1D may increase their cardiometabolic risk.

STUDY OBJECTIVES MAIN OBJECTIVE: Unveiling the pathogenic mechanisms behind functional hyperandrogenism in women with T1D from a sex medicine perspective.

1. Primary aims: To identify predisposing/protective factors associated with the development of functional hyperandrogenism in women with T1D by phenotyping these women using state-of-the-art techniques for the assessment of:

   1.1. Insulin sensitivity. 1.2. Body composition. 1.3. Ovarian and adrenal steroidogenesis.

2. Secondary aims: Identification of relevant molecular-genetic factors associated with the development of functional hyperandrogenism in women with T1D 2.1. Identify genomic variants in genes/proteins related to insulin signalling and action, adiposity, inflammation, steroidogenesis, and PCOS itself (Genomics).

   2.2. Description of differential DNA methylation patterns in deep subcutaneous adipose and skeletal muscle tissues (Epigenomics).

   2.3. Description of differential gene expression profiles in adipose and muscle tissues (Transcriptomics).

   2.2. Description of differential proteomic profiles in adipose and muscle tissue (Proteomics).

3. Exploratory aim: To evaluate the interaction between T1D and PCOS on parameters of metabolic control and morbidities associated with T1D itself.

• Study Type: Observational
• Enrollment (Estimated): 60

Contacts and Locations

• Study Contact: Name: Manuel Luque-Ramírez, Principal Investigator, PhD, MD, MBA; Phone Number: 9029 +34 913368000; Email: manuel.luque@salud.madrid.org

Study Locations

• Spain
  • Madrid
    • Madrid, Madrid, Spain, 28034
      • Department of Endocrinology and Clinical Nutrition, Hospital Universitario Ramón y Cajal, Carretera de Colmenar Viejo, Km 9.1, 28034-Madrid (Spain)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Premenopausal adult women with type 1 diabetes mellitus presenting with or without polycystic ovary syndrome.

Description

1. Non--hyperandrogenic women with type 1 diabetes INCLUSION CRITERIA

   • Premenopausal women between 18 and 45 years old.
   • Diagnosis of type 1a diabetes at least 12 months before inclusion in the study, confirmed by positive autoimmunity and complete insulin deficiency.
   • Treatment with subcutaneous insulin therapy (multiple doses or continuous infusion).
   • Availability of metabolic control data (continuous interstitial blood glucose monitoring) at least in the month prior to study entry.
   • Menarche at least three years prior to study entry. EXCLUSION CRITERIA
   • Honeymoon period of T1D.
   • Pregnancy or lactation.
   • Thyroid hormone dysfunction or hyperprolactinaemia.
   • Diagnosis of non-classical congenital adrenal hyperplasia or other secondary causes of hyperandrogenism.
   • Diagnosis of other serious chronic disease.
   • Treatment with oral contraceptives or glucocorticoid therapy in the 3 months prior to inclusion in the study.

2. Women with type 1 diabetes and polycystic ovary syndrome INCLUSION CRITERIA

   • Women between 18 and 45 years old.
   • Diagnosis of type 1a diabetes at least 12 months before inclusion in the study, confirmed by positive autoimmunity and complete insulin deficiency.
   • Treatment with subcutaneous insulin therapy (multiple doses or continuous infusion).
   • Availability of metabolic control data (continuous interstitial blood glucose monitoring) at least in the month prior to study entry.
   • Menarche at least three years prior to study entry.
   • PCOS diagnosis based on the 2012 American NIH consensus criteria, including the Rotterdam and AE-PCOS.

   EXCLUSION CRITERIA

   • Honeymoon period of T1D.
   • Pregnancy/lactation.
   • Thyroid hormone dysfunction or hyperprolactinaemia.
   • Diagnosis of non-classical congenital adrenal hyperplasia or other secondary causes of hyperandrogenism.
   • Diagnosis of other serious chronic disease. reatment with oral contraceptives or glucocorticoid therapy in the 3 months prior to inclusion in the study.

3. Men with T1D and normal gonadal function of similar age, BMI, and duration of diabetes.

   INCLUSION CRITERIA

   • Age between 18 and 45 years old.
   • Diagnosis of type 1a diabetes at least 12 months before inclusion in the study, confirmed by positive autoimmunity and complete insulin deficiency.
   • Treatment with subcutaneous insulin therapy (multiple doses or continuous infusion).
   • Availability of metabolic control data (continuous interstitial blood glucose monitoring) at least in the month prior to study entry.

   EXCLUSION CRITERIA

   • Honeymoon period of T1D.
   • Thyroid hormone dysfunction or hyperprolactinaemia.
   • Diagnosis of non-classical congenital adrenal hyperplasia.
   • Diagnosis of male hypogonadism.

4. Women with PCOS of similar age and BMI. INCLUSION CRITERIA

   • Women between 18 and 45 years old.
   • Menarche at least three years prior to study entry.
   • PCOS diagnosis based on the 2012 American NIH consensus criteria, including the Rotterdam and AE-PCOS.

   EXCLUSION CRITERIA

   • Pregnancy/lactation.
   • Previously known carbohydrate metabolism abnormalities (prediabetes or type 2 diabetes).
   • Thyroid hormone dysfunction or hyperprolactinaemia.
   • Diagnosis of non-classical congenital adrenal hyperplasia or other secondary causes of hyperandrogenism.
   • Diagnosis of other serious chronic disease.
   • Treatment with oral contraceptives or glucocorticoid therapy in the 3 months prior to inclusion in the study.

5. Non-hyperandrogenic control women with regular menses of similar age and BMI. INCLUSION CRITERIA

   • Women between 18 and 45 years old.
   • Menarche at least three years prior to study entry.
   • Presence of regular menses.
   • Lack of signs or symptoms of functional hyperandrogenism. EXCLUSION CRITERIA
   • Pregnancy/lactation.
   • Previously known carbohydrate metabolism disturbances.
   • Thyroid hormone dysfunction or hyperprolactinaemia.
   • Diagnosis of non-classical congenital adrenal hyperplasia or other secondary causes of hyperandrogenism.
   • Diagnosis of other serious chronic disease.
   • Treatment with oral contraceptives or glucocorticoid therapy in the 3 months prior to inclusion in the study.

Study Plan

How is the study designed?

Number of groups / cohorts

5

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Non--hyperandrogenic women with type 1 diabetes; INCLUSION CRITERIA; Premenopausal women between 18 and 45 years old.; Diagnosis of type 1a diabetes at least 12 months before inclusion in the study, confirmed by positive autoimmunity and complete insulin deficiency.; Treatment with subcutaneous insulin therapy (multiple doses or continuous infusion).; Availability of metabolic control data (continuous interstitial blood glucose monitoring) at least in the month prior to study entry.; Menarche at least three years prior to study entry. EXCLUSION CRITERIA; Honeymoon period of T1D.; Pregnancy or lactation.; Thyroid hormone dysfunction or hyperprolactinaemia.; Diagnosis of non-classical congenital adrenal hyperplasia or other secondary causes of hyperandrogenism.; Diagnosis of other serious chronic disease.; Treatment with oral contraceptives or glucocorticoid therapy in the 3 months prior to inclusion in the study.	Other: Type 1 diabetes mellitus; A diagnosis of type 1a diabetes mellitus; Other: Sex dimorphism; Effects of sex on outcomes measures
Women with type 1 diabetes and polycystic ovary syndrome; INCLUSION CRITERIA; Women between 18 and 45 years old.; Diagnosis of type 1a diabetes at least 12 months before inclusion in the study, confirmed by positive autoimmunity and complete insulin deficiency.; Treatment with subcutaneous insulin therapy (multiple doses or continuous infusion).; Availability of metabolic control data (continuous interstitial blood glucose monitoring) at least in the month prior to study entry.; Menarche at least three years prior to study entry.; PCOS diagnosis based on the 2012 American NIH consensus criteria, including the Rotterdam and AE-PCOS. EXCLUSION CRITERIA; Honeymoon period of T1D.; Pregnancy/lactation.; Thyroid hormone dysfunction or hyperprolactinaemia.; Diagnosis of non-classical congenital adrenal hyperplasia or other secondary causes of hyperandrogenism.; Diagnosis of other serious chronic disease. reatment with oral contraceptives or glucocorticoid therapy in the 3 months prior to inclusion in the study.	Other: Type 1 diabetes mellitus; A diagnosis of type 1a diabetes mellitus; Other: Sex dimorphism; Effects of sex on outcomes measures; Other: Elevated circulating androgen levels; Androgen excess exposition due to a diagnosis of polycystic syndrome or male sex
Men with T1D and normal gonadal function of similar age, BMI, and duration of diabetes.; INCLUSION CRITERIA; Age between 18 and 45 years old.; Diagnosis of type 1a diabetes at least 12 months before inclusion in the study, confirmed by positive autoimmunity and complete insulin deficiency.; Treatment with subcutaneous insulin therapy (multiple doses or continuous infusion).; Availability of metabolic control data (continuous interstitial blood glucose monitoring) at least in the month prior to study entry. EXCLUSION CRITERIA; Honeymoon period of T1D.; Thyroid hormone dysfunction or hyperprolactinaemia.; Diagnosis of non-classical congenital adrenal hyperplasia.; Diagnosis of male hypogonadism.	Other: Type 1 diabetes mellitus; A diagnosis of type 1a diabetes mellitus; Other: Sex dimorphism; Effects of sex on outcomes measures; Other: Elevated circulating androgen levels; Androgen excess exposition due to a diagnosis of polycystic syndrome or male sex
Women with PCOS of similar age and BMI.; INCLUSION CRITERIA; Women between 18 and 45 years old.; Menarche at least three years prior to study entry.; PCOS diagnosis based on the 2012 American NIH consensus criteria, including the Rotterdam and AE-PCOS. EXCLUSION CRITERIA; Pregnancy/lactation.; Previously known carbohydrate metabolism abnormalities (prediabetes or type 2 diabetes).; Thyroid hormone dysfunction or hyperprolactinaemia.; Diagnosis of non-classical congenital adrenal hyperplasia or other secondary causes of hyperandrogenism.; Diagnosis of other serious chronic disease.; Treatment with oral contraceptives or glucocorticoid therapy in the 3 months prior to inclusion in the study.	Other: Sex dimorphism; Effects of sex on outcomes measures; Other: Elevated circulating androgen levels; Androgen excess exposition due to a diagnosis of polycystic syndrome or male sex
Non-hyperandrogenic control women with regular menses of similar age and BMI; INCLUSION CRITERIA; Women between 18 and 45 years old.; Menarche at least three years prior to study entry.; Presence of regular menses.; Lack of signs or symptoms of functional hyperandrogenism. EXCLUSION CRITERIA; Pregnancy/lactation.; Previously known carbohydrate metabolism disturbances.; Thyroid hormone dysfunction or hyperprolactinaemia.; Diagnosis of non-classical congenital adrenal hyperplasia or other secondary causes of hyperandrogenism.; Diagnosis of other serious chronic disease.; Treatment with oral contraceptives or glucocorticoid therapy in the 3 months prior to inclusion in the study.	Other: Sex dimorphism; Effects of sex on outcomes measures

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Differences in insulin sensitivity between study subgroups	Study of sensitivity to insulin action by hyperinsulinaemic euglycaemic clamp. Clamping will be conducted in the follicular phase fo women's study participants. In this protocol free fatty acids will be also determined in stored samples.	At baseline
Fat mass percentage	Body composition studies: Fat mass percentage with respect to total body weight. Methodology: Bioelectrical impedance analysis by Monitor VitalScan Medeia® System device (United States, CA).	At baseline
Phase angle 50 KHz	Methodology: Bioelectrical impedance analysis by Monitor VitalScan Medeia® System device (United States, CA).	At baseline
Peritoneum-vertebral column fat thickness	Ultrasound assessment of fat compartments, determined using Toshiba Nemio ZG SSA-580ª ultrasound equipment (Toshiba Medical Systems, S.A., Alcobendas, Madrid) following the protocol previously validated and reported by our research group (PMID: 23386652).	At baseline
Trunk fat mass %	Dual energy X-ray absorptiometry (DEXA). Hologic QDR Explorer® equipment.	At baseline
Differences in ovarian and adrenal steroidogenesis between study subgroups	The circulating sex steroid profile will be assessed at baseline and at 60 minutes after stimulation of adrenal steroidogenesis with administration of 250 mcg i.v. of 1-24 ACTH. This profile will be determined in serum samples by liquid chromatography followed by tandem mass spectrometry (LC-MS/MS) at the Laboratory of Clinical Biology, Ghent University, Belgium, using a triple-quadrupole mass spectrometer (AB Sciex, Toronto, Canada). The 24h urine steroid metabolomic profile will be analysed by gas chromatography-mass spectrometry (GC-MS). The analytical procedure will be performed by pre-extraction of urine (solid phase extraction with Sep-Pak C18 columns), followed by hydrolysis, solid phase re-extraction and double derivatization of the steroids to their methoxymethyltrimethylsilyl derivatives. The extracts obtained will be injected into the Shimadzu GCMS QP2010 instrument.	At baseline

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Identify genomic variants in genes/proteins related to insulin signalling and action, adiposity, inflammation, steroidogenesis, and PCOS itself	This approach will permit a detailed characterization of all the genetic variants present in the coding portion of the human genome, covering not only genes already identified to be associated with PCOS, but also other genes related to the pathophysiology of PCOS in women with T1D. Bioinformatic analysis of WES will be focused on genes that have been linked to PCOS and functional hyperandrogenism in populations of European ancestry in previous candidate gene studies and genome wide association studies, leaving open the possibility of analyzing other genes of interest depending on the results obtained in other studies of the project and the data published by other groups. Genomic DNA will be isolated from peripheral bood with the FlexiGene DNA Qiagen kit and submitted to an external biotech company (Macrogen Spain) for conducting these studies. Genomic DNA will be isolated from peripheral blood with the FlexiGene DNA Qiagen kit and submitted to an external biotech company.	At baseline
Description of differential DNA methylation patterns in deep subcutaneous adipose and skeletal muscle tissues (Epigenomics)	Oxford Nanopore sequencing enables direct detection of methylated cytosines from isolated genomic DNA without the need for bisulphite conversion. The Adaptive Sampling RRMS panel (Reduced Representation Methylation Sequencing) protocol enables to target the regions of human genome highly enriched for CpG sites, including a total number of 7-8M CpGs, and multiplexing up to 4 samples on a single PromethION flow cell.	At baseline
Description of differential gene expression profiles in adipose and muscle tissues (Transcriptomics)	RNA from adipose and muscle will be isolated using the Fatty Tissue and Total RNA Purification kits (Norgen Biotek). RNA quantity and quality shall be evaluated with the Qubit fluorimeter and Agilent Bioanalyzer. RNAseq libraries will be prepared following the protocol included in the Illumina® Stranded Total RNA Prep, Ligation with Ribo-Zero Plus kit. Sequencing will be performed using an Illumina NovaSeqXPlus (1x100bp) with >40M reads/sample. Targeted expression of selected genes (chosen according RNAseq results) will be assessed by real-time qPCR in a LightCycler480 with products from AnyGenes company.	At baseline
Description of differential proteomic profiles in adipose and muscle tissue (Proteomics)	Comparative proteome analysis with isobaric tandem mass tag (TMT). Samples will be processed according to the protocol described in Carmona L. et al. (PMID: 37171157) on S-Trap columns. The resulting peptides will be labelled with TMT18plex labels according to the manufacturer's instructions (Thermo Scientific). The labelled peptides shall be separated on an Ultimate 3000 nanochromatograph on a C18 reverse phase column.	At baseline

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Insulin requirements/day adjusted for weight	To evaluate the interaction between T1D and PCOS on parameters of metabolic control and morbidities associated with T1D itself.	At baseline
Time in range	Interstitial blood glucose monitoring: time in range [between 70 and 180 mg/dl (%)]	Since 4 weeks prior to inclusion in study
Ambulatory blood pressure	Blood pressure determined according to 24-hour ambulatory blood pressure monitoring	At baseline
Subclinical atherosclerosis: Differences in carotid intimomedial thickness between study subgroups	Imaging will be conducted using a high-resolution 7-15 MHz phased-array transducer (EPIQ 5, Philips Healthcare, Bothell, WA, USA) by the same trained operator in all study participants. This operator will be blinded to the women's features and their group allocation. Under controlled light and temperature conditions, studies will be performed by positioning the women in a supine position with a 35-degree incline of the head and torso, and a 45 degrees right-turn or left-turn, respectively, of the head. The left and right common carotid arteries will be explored in B-mode in longitudinal and transversal planes, to rule out the presence of plaque that might interfere with cIMT measurements. The posterior carotid wall at 1 cm of the common carotid bulb will be imaged and cIMT estimated by visual assessment (average of five manual measurements) of the distance between the lumen/intima and intima/adventitia interphases in longitudinal frames acquired during arterial diastole.	At baseline

Collaborators and Investigators

• Sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
• Collaborators: University of Alcala; Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders
• Investigators: Principal Investigator: Manuel Luque-Ramírez, PhD, MD, MBA, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) & CIBERDEM & Universidad de Alcalá de Henares

Publications and helpful links

General Publications

• Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000 Jul;85(7):2434-8. doi: 10.1210/jcem.85.7.6682.
• Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012 Dec;33(6):981-1030. doi: 10.1210/er.2011-1034. Epub 2012 Oct 12.
• Manneras-Holm L, Leonhardt H, Kullberg J, Jennische E, Oden A, Holm G, Hellstrom M, Lonn L, Olivecrona G, Stener-Victorin E, Lonn M. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab. 2011 Feb;96(2):E304-11. doi: 10.1210/jc.2010-1290. Epub 2010 Nov 17.
• Victor VM, Rocha M, Banuls C, Alvarez A, de Pablo C, Sanchez-Serrano M, Gomez M, Hernandez-Mijares A. Induction of oxidative stress and human leukocyte/endothelial cell interactions in polycystic ovary syndrome patients with insulin resistance. J Clin Endocrinol Metab. 2011 Oct;96(10):3115-22. doi: 10.1210/jc.2011-0651. Epub 2011 Jul 21.
• Escobar-Morreale HF, Roldan B, Barrio R, Alonso M, Sancho J, de la Calle H, Garcia-Robles R. High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus. J Clin Endocrinol Metab. 2000 Nov;85(11):4182-7. doi: 10.1210/jcem.85.11.6931.
• Roldan B, Escobar-Morreale HF, Barrio R, de La Calle H, Alonso M, Garcia-Robles R, Sancho J. Identification of the source of androgen excess in hyperandrogenic type 1 diabetic patients. Diabetes Care. 2001 Jul;24(7):1297-9. doi: 10.2337/diacare.24.7.1297. No abstract available.
• Escobar-Morreale HF, Bayona A, Nattero-Chavez L, Luque-Ramirez M. Type 1 diabetes mellitus and polycystic ovary syndrome. Nat Rev Endocrinol. 2021 Dec;17(12):701-702. doi: 10.1038/s41574-021-00576-0. No abstract available.
• Ortiz-Flores AE, Luque-Ramirez M, Fernandez-Duran E, Alvarez-Blasco F, Escobar-Morreale HF. Diagnosis of disorders of glucose tolerance in women with polycystic ovary syndrome (PCOS) at a tertiary care center: fasting plasma glucose or oral glucose tolerance test? Metabolism. 2019 Apr;93:86-92. doi: 10.1016/j.metabol.2019.01.015. Epub 2019 Jan 30.
• Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018 May;14(5):270-284. doi: 10.1038/nrendo.2018.24. Epub 2018 Mar 23.
• Luque-Ramirez M, Escobar-Morreale HF. Polycystic ovary syndrome as a paradigm for prehypertension, prediabetes, and preobesity. Curr Hypertens Rep. 2014 Dec;16(12):500. doi: 10.1007/s11906-014-0500-6.
• Escobar-Morreale HF, Alvarez-Blasco F, Botella-Carretero JI, Luque-Ramirez M. The striking similarities in the metabolic associations of female androgen excess and male androgen deficiency. Hum Reprod. 2014 Oct 10;29(10):2083-91. doi: 10.1093/humrep/deu198. Epub 2014 Aug 7.
• Luque-Ramirez M, Marti D, Fernandez-Duran E, Alpanes M, Alvarez-Blasco F, Escobar-Morreale HF. Office blood pressure, ambulatory blood pressure monitoring, and echocardiographic abnormalities in women with polycystic ovary syndrome: role of obesity and androgen excess. Hypertension. 2014 Mar;63(3):624-9. doi: 10.1161/HYPERTENSIONAHA.113.02468. Epub 2013 Dec 9.
• Borruel S, Fernandez-Duran E, Alpanes M, Marti D, Alvarez-Blasco F, Luque-Ramirez M, Escobar-Morreale HF. Global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab. 2013 Mar;98(3):1254-63. doi: 10.1210/jc.2012-3698. Epub 2013 Feb 5.
• Escobar-Morreale HF, Samino S, Insenser M, Vinaixa M, Luque-Ramirez M, Lasuncion MA, Correig X. Metabolic heterogeneity in polycystic ovary syndrome is determined by obesity: plasma metabolomic approach using GC-MS. Clin Chem. 2012 Jun;58(6):999-1009. doi: 10.1373/clinchem.2011.176396. Epub 2012 Mar 16.
• Murri M, Luque-Ramirez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update. 2013 May-Jun;19(3):268-88. doi: 10.1093/humupd/dms059. Epub 2013 Jan 9.
• Martinez-Garcia MA, Montes-Nieto R, Fernandez-Duran E, Insenser M, Luque-Ramirez M, Escobar-Morreale HF. Evidence for masculinization of adipokine gene expression in visceral and subcutaneous adipose tissue of obese women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab. 2013 Feb;98(2):E388-96. doi: 10.1210/jc.2012-3414. Epub 2013 Jan 21.
• 2018 ESC/ESH Guidelines for the management of arterial hypertension. Rev Esp Cardiol (Engl Ed). 2019 Feb;72(2):160. doi: 10.1016/j.rec.2018.12.004. No abstract available. English, Spanish.
• Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012 Nov-Dec;18(6):618-37. doi: 10.1093/humupd/dms030. Epub 2012 Jul 4.
• Riestenberg C, Jagasia A, Markovic D, Buyalos RP, Azziz R. Health Care-Related Economic Burden of Polycystic Ovary Syndrome in the United States: Pregnancy-Related and Long-Term Health Consequences. J Clin Endocrinol Metab. 2022 Jan 18;107(2):575-585. doi: 10.1210/clinem/dgab613.
• Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018 Sep 1;33(9):1602-1618. doi: 10.1093/humrep/dey256. Erratum In: Hum Reprod. 2019 Feb 1;34(2):388. doi: 10.1093/humrep/dey363.
• Day F, Karaderi T, Jones MR, Meun C, He C, Drong A, Kraft P, Lin N, Huang H, Broer L, Magi R, Saxena R, Laisk T, Urbanek M, Hayes MG, Thorleifsson G, Fernandez-Tajes J, Mahajan A, Mullin BH, Stuckey BGA, Spector TD, Wilson SG, Goodarzi MO, Davis L, Obermayer-Pietsch B, Uitterlinden AG, Anttila V, Neale BM, Jarvelin MR, Fauser B, Kowalska I, Visser JA, Andersen M, Ong K, Stener-Victorin E, Ehrmann D, Legro RS, Salumets A, McCarthy MI, Morin-Papunen L, Thorsteinsdottir U, Stefansson K; 23andMe Research Team; Styrkarsdottir U, Perry JRB, Dunaif A, Laven J, Franks S, Lindgren CM, Welt CK. Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. PLoS Genet. 2018 Dec 19;14(12):e1007813. doi: 10.1371/journal.pgen.1007813. eCollection 2018 Dec.
• Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev. 2005 Apr;26(2):251-82. doi: 10.1210/er.2004-0004. Epub 2004 Nov 23.
• Hernandez-Mijares A, Rocha M, Rovira-Llopis S, Banuls C, Bellod L, de Pablo C, Alvarez A, Roldan-Torres I, Sola-Izquierdo E, Victor VM. Human leukocyte/endothelial cell interactions and mitochondrial dysfunction in type 2 diabetic patients and their association with silent myocardial ischemia. Diabetes Care. 2013 Jun;36(6):1695-702. doi: 10.2337/dc12-1224. Epub 2013 Jan 8.
• Huang ZH, Manickam B, Ryvkin V, Zhou XJ, Fantuzzi G, Mazzone T, Sam S. PCOS is associated with increased CD11c expression and crown-like structures in adipose tissue and increased central abdominal fat depots independent of obesity. J Clin Endocrinol Metab. 2013 Jan;98(1):E17-24. doi: 10.1210/jc.2012-2697. Epub 2012 Nov 1.
• Gonzalez F, Sia CL, Bearson DM, Blair HE. Hyperandrogenism induces a proinflammatory TNFalpha response to glucose ingestion in a receptor-dependent fashion. J Clin Endocrinol Metab. 2014 May;99(5):E848-54. doi: 10.1210/jc.2013-4109. Epub 2014 Feb 10.
• Escobar-Morreale HF, Luque-Ramirez M, Gonzalez F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril. 2011 Mar 1;95(3):1048-58.e1-2. doi: 10.1016/j.fertnstert.2010.11.036. Epub 2010 Dec 17.
• Murdolo G, Bartolini D, Tortoioli C, Piroddi M, Iuliano L, Galli F. Lipokines and oxysterols: novel adipose-derived lipid hormones linking adipose dysfunction and insulin resistance. Free Radic Biol Med. 2013 Dec;65:811-820. doi: 10.1016/j.freeradbiomed.2013.08.007. Epub 2013 Aug 16.
• Chazenbalk G, Singh P, Irge D, Shah A, Abbott DH, Dumesic DA. Androgens inhibit adipogenesis during human adipose stem cell commitment to preadipocyte formation. Steroids. 2013 Sep;78(9):920-6. doi: 10.1016/j.steroids.2013.05.001. Epub 2013 May 23.
• Glueck CJ, Morrison JA, Daniels S, Wang P, Stroop D. Sex hormone-binding globulin, oligomenorrhea, polycystic ovary syndrome, and childhood insulin at age 14 years predict metabolic syndrome and class III obesity at age 24 years. J Pediatr. 2011 Aug;159(2):308-13.e2. doi: 10.1016/j.jpeds.2011.01.018. Epub 2011 Mar 1.
• Escobar-Morreale HF, Santacruz E, Luque-Ramirez M, Botella Carretero JI. Prevalence of 'obesity-associated gonadal dysfunction' in severely obese men and women and its resolution after bariatric surgery: a systematic review and meta-analysis. Hum Reprod Update. 2017 Jul 1;23(4):390-408. doi: 10.1093/humupd/dmx012.
• Alvarez-Blasco F, Botella-Carretero JI, San Millan JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med. 2006 Oct 23;166(19):2081-6. doi: 10.1001/archinte.166.19.2081.
• Kempna P, Hofer G, Mullis PE, Fluck CE. Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2. Mol Pharmacol. 2007 Mar;71(3):787-98. doi: 10.1124/mol.106.028902. Epub 2006 Nov 30.
• Carbunaru G, Prasad P, Scoccia B, Shea P, Hopwood N, Ziai F, Chang YT, Myers SE, Mason JI, Pang S. The hormonal phenotype of Nonclassic 3 beta-hydroxysteroid dehydrogenase (HSD3B) deficiency in hyperandrogenic females is associated with insulin-resistant polycystic ovary syndrome and is not a variant of inherited HSD3B2 deficiency. J Clin Endocrinol Metab. 2004 Feb;89(2):783-94. doi: 10.1210/jc.2003-030934.
• Gambineri A, Fanelli F, Tomassoni F, Munarini A, Pagotto U, Andrew R, Walker BR, Pasquali R. Tissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 in overweight/obese women with polycystic ovary syndrome compared with weight-matched controls. Eur J Endocrinol. 2014 Jul;171(1):47-57. doi: 10.1530/EJE-13-1030. Epub 2014 Apr 17.
• Rask E, Walker BR, Soderberg S, Livingstone DE, Eliasson M, Johnson O, Andrew R, Olsson T. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab. 2002 Jul;87(7):3330-6. doi: 10.1210/jcem.87.7.8661.
• Luque-Ramirez M, Escobar-Morreale HF. Adrenal Hyperandrogenism and Polycystic Ovary Syndrome. Curr Pharm Des. 2016;22(36):5588-5602. doi: 10.2174/1381612822666160720150625.
• Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016 Oct;37(5):467-520. doi: 10.1210/er.2015-1104. Epub 2016 Jul 26.
• Wickenheisser JK, Biegler JM, Nelson-Degrave VL, Legro RS, Strauss JF 3rd, McAllister JM. Cholesterol side-chain cleavage gene expression in theca cells: augmented transcriptional regulation and mRNA stability in polycystic ovary syndrome. PLoS One. 2012;7(11):e48963. doi: 10.1371/journal.pone.0048963. Epub 2012 Nov 14.
• Tee MK, Miller WL. Phosphorylation of human cytochrome P450c17 by p38alpha selectively increases 17,20 lyase activity and androgen biosynthesis. J Biol Chem. 2013 Aug 16;288(33):23903-13. doi: 10.1074/jbc.M113.460048. Epub 2013 Jul 8.
• Nelson-Degrave VL, Wickenheisser JK, Hendricks KL, Asano T, Fujishiro M, Legro RS, Kimball SR, Strauss JF 3rd, McAllister JM. Alterations in mitogen-activated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome. Mol Endocrinol. 2005 Feb;19(2):379-90. doi: 10.1210/me.2004-0178. Epub 2004 Oct 28.
• Wickenheisser JK, Nelson-DeGrave VL, McAllister JM. Human ovarian theca cells in culture. Trends Endocrinol Metab. 2006 Mar;17(2):65-71. doi: 10.1016/j.tem.2006.01.003. Epub 2006 Feb 7.
• Wickenheisser JK, Nelson-Degrave VL, McAllister JM. Dysregulation of cytochrome P450 17alpha-hydroxylase messenger ribonucleic acid stability in theca cells isolated from women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005 Mar;90(3):1720-7. doi: 10.1210/jc.2004-1860. Epub 2004 Dec 14.
• Wickenheisser JK, Nelson-DeGrave VL, Quinn PG, McAllister JM. Increased cytochrome P450 17alpha-hydroxylase promoter function in theca cells isolated from patients with polycystic ovary syndrome involves nuclear factor-1. Mol Endocrinol. 2004 Mar;18(3):588-605. doi: 10.1210/me.2003-0090. Epub 2003 Dec 18.
• Wickenheisser JK, Quinn PG, Nelson VL, Legro RS, Strauss JF 3rd, McAllister JM. Differential activity of the cytochrome P450 17alpha-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells. J Clin Endocrinol Metab. 2000 Jun;85(6):2304-11. doi: 10.1210/jcem.85.6.6631.
• Moghetti P, Tosi F, Bonin C, Di Sarra D, Fiers T, Kaufman JM, Giagulli VA, Signori C, Zambotti F, Dall'Alda M, Spiazzi G, Zanolin ME, Bonora E. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2013 Apr;98(4):E628-37. doi: 10.1210/jc.2012-3908. Epub 2013 Mar 8.
• Snell-Bergeon JK, Dabelea D, Ogden LG, Hokanson JE, Kinney GL, Ehrlich J, Rewers M. Reproductive history and hormonal birth control use are associated with coronary calcium progression in women with type 1 diabetes mellitus. J Clin Endocrinol Metab. 2008 Jun;93(6):2142-8. doi: 10.1210/jc.2007-2025. Epub 2008 Mar 18.
• Amin R, Schultz C, Ong K, Frystyk J, Dalton RN, Perry L, Orskov H, Dunger DB; Oxford Regional Prospective Study. Low IGF-I and elevated testosterone during puberty in subjects with type 1 diabetes developing microalbuminuria in comparison to normoalbuminuric control subjects: the Oxford Regional Prospective Study. Diabetes Care. 2003 May;26(5):1456-61. doi: 10.2337/diacare.26.5.1456.
• Caumo A, Luzi L. First-phase insulin secretion: does it exist in real life? Considerations on shape and function. Am J Physiol Endocrinol Metab. 2004 Sep;287(3):E371-85. doi: 10.1152/ajpendo.00139.2003.
• Stener-Victorin E, Deng Q. Epigenetic inheritance of polycystic ovary syndrome - challenges and opportunities for treatment. Nat Rev Endocrinol. 2021 Sep;17(9):521-533. doi: 10.1038/s41574-021-00517-x. Epub 2021 Jul 7.
• Luque-Ramirez M, San Millan JL, Escobar-Morreale HF. Genomic variants in polycystic ovary syndrome. Clin Chim Acta. 2006 Apr;366(1-2):14-26. doi: 10.1016/j.cca.2005.10.017. Epub 2005 Dec 7.
• Wekker V, van Dammen L, Koning A, Heida KY, Painter RC, Limpens J, Laven JSE, Roeters van Lennep JE, Roseboom TJ, Hoek A. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Hum Reprod Update. 2020 Nov 1;26(6):942-960. doi: 10.1093/humupd/dmaa029.
• Kakoly NS, Khomami MB, Joham AE, Cooray SD, Misso ML, Norman RJ, Harrison CL, Ranasinha S, Teede HJ, Moran LJ. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. Hum Reprod Update. 2018 Jul 1;24(4):455-467. doi: 10.1093/humupd/dmy007.
• Chiaffarino F, Cipriani S, Dalmartello M, Ricci E, Esposito G, Fedele F, La Vecchia C, Negri E, Parazzini F. Prevalence of polycystic ovary syndrome in European countries and USA: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2022 Dec;279:159-170. doi: 10.1016/j.ejogrb.2022.10.020. Epub 2022 Oct 28.
• Bayona A, Martinez-Vaello V, Zamora J, Nattero-Chavez L, Luque-Ramirez M, Escobar-Morreale HF. Prevalence of PCOS and related hyperandrogenic traits in premenopausal women with type 1 diabetes: a systematic review and meta-analysis. Hum Reprod Update. 2022 Jun 30;28(4):501-517. doi: 10.1093/humupd/dmac011.

Study record dates

Study Major Dates

• Study Start (Estimated): April 1, 2026
• Primary Completion (Estimated): June 30, 2028
• Study Completion (Estimated): December 31, 2028

Study Registration Dates

• First Submitted: March 12, 2026
• First Submitted That Met QC Criteria: March 18, 2026
• First Posted (Actual): March 24, 2026

Study Record Updates

• Last Update Posted (Actual): April 22, 2026
• Last Update Submitted That Met QC Criteria: April 18, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: Genetics; Insulin resistance; Body composition; Type 1 diabetes; Pathogenesis; Epigenetics; Hyperandrogenism; Steroidogenesis
• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Endocrine System Diseases; Neoplasms; Male Urogenital Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Metabolic Diseases; Autoimmune Diseases; Immune System Diseases; Genital Diseases, Female; Glucose Metabolism Disorders; Diabetes Mellitus; Ovarian Diseases; Adnexal Diseases; Gonadal Disorders; Congenital Abnormalities; Hyperinsulinism; Ovarian Cysts; Cysts; Disorders of Sex Development; Urogenital Abnormalities; 46, XX Disorders of Sex Development; Adrenogenital Syndrome; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Polycystic Ovary Syndrome; Diabetes Mellitus, Type 1; Insulin Resistance; Hyperandrogenism; Reproductive Physiological Phenomena; Reproductive and Urinary Physiological Phenomena; Sex Characteristics
• Other Study ID Numbers: PI250434

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: All data sets generated and/or analyzed during the current study will not be publicly available but will be available from the Principal Investigator on reasonable request.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No